Idarubicin
Class
Topoisomerase inhibitors
Subclass
Anthracyclines
Substance name
IDArubicin hydrochloride
Brand names
Idamycin PFS®
Common formulations
Solution for injection
Dosage and administration
Adults patients
Treatment of acute myeloid leukemia • Newly-diagnosed CD33-positive
Other off-label uses
Indications for use
Labeled indications
Adults
Off-label indications
Adults
Safety risks
Boxed warnings
Congestive HF
Contraindications
Known idarubicin or other anthracycline hypersensitivity or anthracenedione hypersensitivity
Platelet counts < 50,000/mm3 (Intramuscular injections)
Warnings and precautions
Bleeding
Chemotherapy-induced bone marrow suppression
Tumor lysis syndrome
Specific populations
Renal impairment
eGFR 20-50 mL/min/1.73 m²
eGFR 10-20 mL/min/1.73 m²
eGFR < 10 mL/min/1.73 m²
Renal replacement therapy
Continuous renal replacement
Intermittent hemodialysis
Peritoneal dialysis
Hepatic impairment
Any severity
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: D
All trimesters • Australia Category: D
Breastfeeding
Little information available on breastfeeding safety.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource